TAO is characterized by a complex molecular mechanism involving interactions at various cellular and molecular levels and is classified as an autoimmune disease. In the context of abnormal thyroid function, the immune system generates antibodies targeting the thyroid-stimulating hormone receptor (TSHR) (14). These antibodies target thyroid cells and influence eye immune and cellular responses. Binding of TSHR antibodies activates receptors via the G protein-coupled signaling pathway, stimulating adenylate cyclase, raising intracellular adenosine monophosphate levels, and triggering cell proliferation and collagen synthesis (15). In TAO, elevated IGF-1R expression interacts with TSHR antibodies, leading to ocular tissue growth and glycosaminoglycan deposition. IGF-1 activates the PI3K/Akt pathway, enhancing cell survival and proliferation (16). Cytokines and inflammatory factors regulate TAO development. TNF-α stimulates fibroblast growth, extracellular matrix production, and inflammatory cell migration. IL-1 and IL-6 enhance inflammation by promoting lymphocyte and macrophage chemotaxis (17). In the context of fibrosis, TGF-β is crucial in TAO-related fibrosis, as it activates fibroblasts and boosts collagen production via the Smad signaling pathway, leading to increased extracellular matrix components like collagen, fibronectin, and glycosaminoglycans (18). Furthermore, in TAO, there is an upregulation of collagen synthesis accompanied by a reduction in its degradation, resulting in collagen accumulation. This alteration is associated with an imbalance in cytokine levels and the regulation of matrix metalloproteinases (19). Regarding immune cell infiltration, the activation and infiltration of macrophages can exacerbate inflammatory responses, thereby facilitating the destruction and fibrosis of ocular tissues (20). The molecular mechanisms underlying TAO are intricate, encompassing the interplay of various cell types, signaling pathways, and molecular mediators. Elucidating and broadening our comprehension of these mechanisms is of paramount importance for the development of novel therapeutic strategies.

Iron, a crucial metallic element, plays a vital role in numerous cellular biological processes, such as oxygen transport and electron transfer (21). Nonetheless, excessive intracellular iron concentrations can facilitate the production of reactive oxygen species (ROS), which are highly reactive molecules that can inflict damage on cellular structures, including DNA, proteins, and lipids (22). Ferroptosis is a unique form of regulated cell death characterized by iron-dependent lipid peroxidation and ROS accumulation (23). Contrasting with apoptosis and necrosis, ferroptosis is primarily driven by a collapse in cellular antioxidant defenses, specifically through glutathione (GSH) depletion and glutathione peroxidase 4 (GPX4) inactivation (24, 25). This process initiates with the accumulation of unbound iron, which catalyzes the formation of highly reactive hydroxyl radicals via the Fenton reaction. These radicals subsequently induce lipid peroxidation, disrupting cellular membranes and ultimately leading to cell death. Morphologically, ferroptotic cells exhibit condensed mitochondria with increased membrane density and reduced or absent cristae—distinct features that differentiate ferroptosis from apoptosis and necrosis (26, 27).

Oxidative stress plays a pivotal role in the pathogenesis of TAO. In affected individuals, elevated ROS levels or a reduced antioxidant ability can lead to oxidative damage in cellular membranes, lipid peroxidation, and DNA oxidation. This stress response is characterized by significantly increased levels of lipid peroxides, superoxide dismutase (SOD), glutathione reductase, and glutathione peroxidase within the orbital connective tissue, alongside a decrease in glutathione, a major antioxidant (28). Furthermore, modulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/extracellular signal-regulated kinases (ERK)/heme oxygenase-1 (HO-1) signaling pathway has shown potential in mitigating oxidative stress in orbital fibroblasts (29). In addition, increased expression of endoplasmic reticulum stress (ER)-related genes, such as activating transcription factor 6, phospho-ERK, and inositol-requiring enzyme 1α, has been observed in the orbital tissues of TAO patients compared to controls (30). Inhibition of phospho-ERK has been shown to reduce oxidative stress and lipid synthesis in TAO orbital fibroblasts (31). Epigenetic regulators, particularly histone deacetylases, play a pivotal role in modulating immune response and fibrosis in TAO (32). Additionally, empirical studies have provided evidence that using RNA aptamers (e.g., CD40Apt) to inhibit the CD40-CD40L signaling pathway can reduce the expression of CD40, collagen I, transforming growth factor beta (TGF-β), and alpha smooth muscle actin (α-SMA) in the orbital muscles and adipose tissue in murine models (33).

Oxidative stress plays a central role in triggering ferroptosis. The fundamental molecular mechanism involves an imbalance between oxidative damage and antioxidant defenses, particularly affecting lipid membranes (34). This process is intensified by iron-catalyzed lipid peroxide formation, which further disrupts the antioxidant defense system—primarily through GSH depletion and GPX4 inhibition—thereby exacerbating oxidative stress and promoting ferroptosis (35). Accumulated lipid peroxides amplify this oxidative stress, creating a self-perpetuating cycle that drives cell death (35). Several antioxidant pathways modulate ferroptosis, including the Xc system - GPX4 pathway, the ferroptosis suppressor protein 1-coenzyme Q10 pathway, the GTP cyclohydrolase 1-tetrahydrobiopterin pathway, and the dihydroorotate dehydrogenase-coenzyme Q10 pathway (36, 37). These pathways are crucial for synthesizing antioxidants like GSH, coenzyme Q10H2, and tetrahydrobiopterin, which collectively mitigate intracellular oxidative stress and prevent ferroptosis (38, 39). During ferroptosis, cellular redox homeostasis is disrupted, with diminished antioxidants such as GSH and GPX4 and increased levels of pro-oxidants, including divalent iron ions and lipid ROS (40). The mitochondria, a primary source of intracellular ROS, are notably implicated in ferroptosis (41). Consequently, oxidative stress represents a significant mechanism contributing to ferroptosis, which plays a role in the onset and progression of TAO. Mitigating oxidative stress or inhibiting ferroptosis may offer multifaceted approaches to controlling the advancement of TAO.

The interplay between ferroptosis and mitochondrial biogenesis is particularly noteworthy. Nrf2, a critical regulator in ferroptosis, influences mitochondrial biogenesis by modulating genes such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha, Nrf1 and Nrf2, transcription factor A mitochondrial, and other mitochondrial genes (42). Furthermore, Nrf2 mediates the regulation of mitochondrial fission, fusion, and autophagy. In conclusion, an aberrant redox system marked by excessive oxidants and depleted antioxidants leads to lipid peroxide accumulation, inducing ferroptosis. This underscores the therapeutic potential of targeting redox homeostasis to prevent ferroptosis-related diseases (43). Moreover, ROS generated during inflammatory responses can induce cellular damage and play a pivotal role in activating ferroptosis. Studies have demonstrated that markers of oxidative stress are elevated in the orbital tissues of TAO patients, indicating that ROS accumulation may instigate ferroptosis in orbital fibroblasts (44). It is important to note that ferroptosis is distinct from apoptosis and necrosis, being driven specifically by iron-catalyzed lipid peroxidation. The involvement of ferroptosis in TAO suggests that targeting oxidative stress and iron metabolism could be effective therapeutic strategies for managing TAO (45). These findings imply that oxidative stress and ferroptosis contribute to TAO pathogenesis by promoting inflammation and tissue remodeling. If oxidative stress and ferroptosis can be jointly suppressed, it may have a better effect.

The pathogenesis of TAO involves a complex interplay among immune cells and cytokines. CD4⁺ T cells, particularly Th1 and Th17 subsets, are central to orchestrating the immune response in TAO. These cells secrete pro-inflammatory cytokines such as interferon-gamma (IFN-γ), interleukin-1 beta (IL-1β), and interleukin-17 (IL-17), which stimulate the activation and proliferation of orbital fibroblasts and adipocytes (46). Additionally, B cells contribute to disease progression by producing autoantibodies against the thyroid stimulating hormone (TSH) receptor and insulin-like growth factor 1 receptor. Macrophages and dendritic cells also participated in the inflammatory milieu of TAO, releasing cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which further amplify tissue inflammation and fibrosis (47). This dysregulation of immune cells and cytokines establishes a pro-inflammatory environment that drives the pathogenesis of TAO. Studies have shown that tea-derived polyphenols can suppress IL-6, IL-1β, and monocyte chemoattractant protein-1 synthesis in TAO orbital fibroblasts via modulation of the nuclear factor kappa B (NF-κB)/NLR family pyrin domain containing 3 (NLRP3) pathways, thereby reducing inflammation triggered by lipopolysaccharide (LPS) (48). In an in vitro model of TGF-β-induced orbital fibroblast activation, inhibition of TGF-β reduced levels of α-SMA, type I collagen, Timp-1, and vimentin, and decreased TGF-β-induced phosphorylation of ERK, p38, JNK, and NF-κB (49). Furthermore, the Janus kinase (JAK)-signal transducer of activation (STAT) signaling pathway has been identified as critical for regulating orbital inflammation in TAO (50, 51). Similarly, activation of the mitogen-activated protein kinases (MAPK)/ERK1/2 signaling pathway promotes orbital fibroblast proliferation and differentiation, exacerbating inflammatory response in TAO orbital tissues (52). TSH has been shown to induce interleukin-1 receptor antagonist (IL-1RA) production in fibroblasts and orbital fibroblasts through the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway (53). Inhibition of PI3K or AKT using small molecule inhibitors, or silencing their expression with small interfering RNA, attenuates TSH’s effects (54). DNA methylation is also implicated in regulating inflammatory receptors and basal metabolic rate in TAO (55), while decreased histone deacetylase 2 expression in ocular tissues enhances T cell proliferation and inflammation in thyroid eye disease (56).

Ferroptosis, characterized by disruptions in redox homeostasis and increased lipid peroxidation, can stimulate inflammatory cells and pathways, leading to pro-inflammatory cytokine production that, in turn, intensifies intracellular oxidative stress and further promotes lipid peroxidation (57). Arachidonic acid (AA) serves as a principal constituent of cell membrane lipids and is metabolized into active pro-inflammatory mediators through three major metabolic pathways. Specifically, AA is converted to prostaglandins via the cyclooxygenase pathway, to leukotrienes and lipoproteins via the lipoxygenase pathway, and to epoxyeicosatrienoic acid and hydroxyeicosatetraenoic acid via the cytochrome P450 pathway (58). Recent studies have elucidated the role of ferroptosis in the NF-κB signaling pathway, where phosphorylation of p65 augments the transcription of lipocalin-2. This reduces extracellular iron uptake, decreasing susceptibility to ferroptosis in hepatic cells (59). In smooth muscle cell studies, NF-κB pathway activation was associated with increased pro-inflammatory cytokine release, including TNF, C-X-C motif ligand (CXCL) 1, CXCL8, and colony-stimulating factor 2. Conversely, treatment with ferroptosis inhibitors reduced the release of TNF-α, IL-1β, and IL-6, thereby alleviating liver damage in experimental models (60). Similarly, dimethyl fumarate, an activator of Nrf2, regulates IκBα and inhibits NF-κB signaling pathway, which, in turn, enhances the transcription of ferroptosis-related protective factors such as heme oxygenase 1, NAD(P)H quinone oxidoreductase 1, and GPX4, therefore providing defense against oxidative stress and ferroptosis (61).

IFN-γ is a critical cytokine in host immunity against tumors, enhancing the susceptibility of tumor cells to ferroptosis through the JAK-STAT signaling pathway (62). IFN-γ therapy has been shown to decelerate the growth of transplanted tumors by promoting lipid oxidation within the host (63). Chromatin immunoprecipitation assays reveal that IFN-γ facilitates the binding of STAT1 to the promoter of solute carrier family 7-member 11 (SLC7A11). Furthermore, the absence of STAT1 abrogates the effects of IFN-γ on ferroptosis and lipid peroxidation (64). In addition to its role in tumor growth, IFN-γ also suppresses the synthesis of GSH through the JAK1/2-STAT1-SLC7A11 signaling pathway, mediating ferroptosis in retinal pigment epithelial cells, which has been linked to in vivo macular degeneration (65).

Similarly, the activation of inflammation through the MAPK pathway is pivotal in triggering ferroptosis (66). In a neonatal rat model subjected to hypoxia-ischemia, the activation of the TLR4-p38 MAPK pathway has been observed (67). This activation increases the production of pro-inflammatory cytokines such as IL-1β, IL-6, and IL-18, while simultaneously inhibiting the expression of SLC7A11 and GPX4 (68). This sequence of molecular events result in neuroinflammation and ferroptosis (69). Additionally, ERK serves as a mediator of the inflammatory response and ferroptosis. Cadmium telluride quantum dot exposure, for example, enhances iron autophagy through the Nrf2-ERK pathway, leading to iron release from labile iron pools, which in turn triggers macrophage ferroptosis and inflammation (70). In conclusion, inflammation not only directly impacts orbital tissue but also exacerbates damage in patients with TAO by serving as an inducing factor for ferroptosis. Consequently, targeting ferroptosis in therapeutic interventions may further mitigate orbital inflammatory responses and confer a protective effect.

The intricate interplay of tissue expansion, remodeling, and fibrosis in TAO significantly contributes to the onset and progression of the disease (71). The pathophysiological mechanisms underlying TAO encompass the infiltration of various immune cells, including CD4⁺ and CD8⁺ T cells, mast cells, and B cells, into orbital tissue. This infiltration results in dysregulated immune responses and abnormal accumulation of hyaluronic acid and glycosaminoglycans (72). TGF-β is central to the development of orbital fibrosis in TAO, mediating tissue fibrosis through both classical and non-classical suppressor of mothers against decapentaplegic (SMAD) signaling pathways (73). Matrix metalloproteinases facilitate the cleavage of latent TGF-β binding protein and latent associated peptide, thereby releasing activated TGF-β, which subsequently engages with TGF-β receptors (74). This receptor interaction induces the phosphorylation of SMAD2/3, resulting in the formation of a complex with SMAD4. The SMAD2/3/4 complex translocates to the nucleus to drive myofibroblast transdifferentiation and extracellular matrix (ECM) production (75). In non-SMAD pathways, TGF-β activates MAPK, PI3K, and Rho-like GTPases, further promoting ECM synthesis and fibroblast transdifferentiation in TAO orbital tissues (76). Inhibiting the p38 or JNK pathways may offer therapeutic potential in treating orbital fibrosis.

Smoking significantly exacerbates orbital fibrosis in TAO patients. IL-1 and ROS produced from cigarette smoke synergistically increase hyaluronic acid production and adipogenesis (77). Furthermore, smoking induces hypoxia-inducible factor-1 (HIF-1) expression, which activates HIF-1-dependent adipogenesis in hypoxic conditions (78). Additionally, smoking exacerbates oxidative stress in TAO orbital fibroblasts, leading to the upregulation of fibrosis-related genes such as apolipoprotein J, connective tissue growth factor, and fibronectin. This process is accompanied by increased levels of TGF-β1 and IL-1β (79).

Non-coding RNAs are also implicated in the regulation of TAO orbital tissue fibrosis. Specifically, miR-146a downregulates fibronectin, collagen I α, and α-SMA proteins in TGF-β-induced TAO orbital fibroblasts via SMAD4 and tumor necrosis factor receptor-associated factor 6 pathways (80). Elevated miR-155 levels and decreased miR-146a levels can promote the proliferation of orbital fibroblasts (81). Furthermore, TSH stimulates the proliferation of orbital fibroblasts through the PI3K/Akt pathway as well as miR-146a and miR-155 (82).

Ferroptosis also plays a significant role in anti-fibrosis mechanisms. Triptolide has been shown to alleviate liver fibrosis by inducing ferroptosis in hepatic stellate cells via HO-1 targeting, offering a novel approach to treating liver fibrosis (83). The induction of ferroptosis in activated hepatic stellate cells is emerging as a promising and innovative approach for liver fibrosis therapy (84). However, research has indicated that excessive iron deposition and ferroptosis in the liver exacerbate acetaminophen-induced liver fibrosis in murine models (85). Consequently, additional research is warranted to elucidate the role of ferroptosis in fibrosis. Specifically, in the context of pulmonary fibrosis, stimulation by TGF-β has been shown to upregulate the expression of transferrin receptor protein 1 in both human lung fibroblasts and primary mouse lung fibroblasts (86). This upregulation results in an increased intracellular concentration of Fe²⁺, thereby facilitating the differentiation of fibroblasts into myofibroblasts (87). Consequently, we propose that ferroptosis may regulate tissue fibrosis through its influence on associated signaling pathways and the enhancement of intercellular interactions. This presents a promising target for antifibrotic therapy in TAO. Furthermore, investigating the inducers and underlying mechanisms of ferroptosis could facilitate the development of novel therapeutic strategies.

In summary, the immunological background of TAO is characterized by a complex interplay of autoimmune responses, involving various immune cells and cytokines, oxidative stress, and ferroptosis ( Figure 1 ). Genetic and epigenetic factors further modulate the susceptibility and progression of the disease. Understanding these interrelated mechanisms is essential for identifying new therapeutic targets, underscoring the importance of an integrative treatment approach for this debilitating condition.

TAO is a multifaceted autoimmune disorder involving various orbital tissues, including extraocular muscles, adipose tissue, and lacrimal glands. Research has identified an age-associated trend in extraocular muscle thickening in TAO patients, with older individuals are more susceptible to posterior orbital extraocular muscle thickening. This thickening can lead to diplopia and restricted ocular motility (88). Furthermore, research indicates that the deprivation of cysteine and/or treatment with erastin can induce ferroptosis, subsequently resulting in the proliferation of orbital fibroblasts (89). In patients with TAO, there is an observed increase in ferroptosis in orbital adipose tissue; however, this does not influence adipocyte proliferation. It is hypothesized that, despite a reduction in GPX4 levels, these adipocytes may exhibit a resemblance to certain tumor cells by maintaining elevated intracellular GSH levels. Consequently, even under conditions of heightened oxidative stress, the residual GSH is essential for neutralizing the substantial amounts of ROS and scavenging lipid peroxides, allowing differentiated adipocytes to resist ferroptosis despite elevated oxidative stress (90). A separate investigation demonstrated that adipocytes have the capacity to secrete fatty acids that promote resistance to ferroptosis in breast cancer cells. This mechanism is reliant on the fatty acid synthase ACSL3, thereby corroborating that breast cancer cells exhibit resistance to ferroptosis when co-cultured with peritumoral adipocytes (91). The function of the lacrimal gland tissue is important for the maintenance of ocular surface health. An investigation into the T-cell immunophenotype of the lacrimal gland in TAO revealed that the inflammation of the lacrimal gland is characterized by a significant infiltration of IFN-γ-producing T helper 1 cells and IL-17A-producing T helper 17 cells. Furthermore, the study demonstrated that IL-17A facilitates the differentiation of lacrimal fibroblasts into either myofibroblasts or adipocytes (92). Furthermore, a study conducted on mice demonstrated that corneal nerve injury induces the upregulation of ferroptosis in lacrimal tissue. This process of ferroptosis subsequently results in damage to the lacrimal tissue, thereby leading to a reduction in tear production (93). In patients with TAO, the synergistic effects of orbital fat accumulation and fibroblast proliferation contribute to infiltrative proptosis, while damage to the lacrimal gland leads to dry eye syndrome. This condition can result in corneal damage due to exposure keratitis, which exacerbates lacrimal gland impairment. Consequently, a self-perpetuating cycle of ocular damage may ensue, potentially leading to further deterioration of ocular health. In conclusion, it is evident that ferroptosis contributes to orbital tissue damage in patients with TAO, leading to orbital fat proliferation, extraocular muscle hypertrophy, and lacrimal gland dysfunction, thereby exacerbating the orbital tissue lesions observed in these patients ( Figure 2 ).

Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, has emerged as a promising therapeutic target in various diseases, including TAO ( Table 1 ). The inhibition of ferroptosis could potentially mitigate the oxidative stress and cellular damage observed in TAO. Understanding the role of ferroptosis in TAO opens new avenues for therapeutic interventions. Ferroptosis inhibitors can prevent cell death through anti-oxidative stress, anti-fibrosis and blocking lipid peroxidation, and may provide a new approach for the treatment of TAO. For instance, the use of sulfasalazine, a clinically used ferroptosis inducer, has shown promising therapeutic effects in thyroid cancer cells, suggesting its potential application in TAO (94, 95). Additionally, targeting ferroptosis-related pathways, such as the ERK/AP-1 pathway, which has been implicated in the protective effects of lutein on TAO, may further enhance therapeutic outcomes (96). Studies have shown that ferroptosis inhibitors, such as liproxstatin-1 and ferrostatin-1, can effectively reduce lipid peroxidation and cell death in models of oxidative stress-related diseases (97–99). Besides, Selenium is an effective drug for treating TAO and is also a key regulator of ferroptosis, because it reduces hydroperoxy groups of complex lipids and silences lipoxygenases (100, 101). By scavenging lipid peroxyl radicals and preventing the accumulation of toxic lipid peroxides, these inhibitors may reduce inflammation and tissue remodeling in the orbit, key pathological features in TAO (102).

Preclinical studies have provided valuable insights into the potential of ferroptosis modulators in the treatment of TAO. For instance, research on thyroid cancer cells has demonstrated that modulating ferroptosis can influence cell viability and oxidative stress responses. In a study involving anaplastic thyroid cancer cells, it was found that these cells could reduce CD71 levels to increase their tolerance to iron overload, thereby resisting ferroptosis (6). This finding suggests that targeting ferroptosis pathways could be a viable approach to managing TAO, where oxidative stress plays a critical role in disease progression. Additionally, the use of ferroptosis inducers, such as erastin, in combination with iron chelators, has shown promise in reducing oxidative damage and improving cell survival in preclinical models (103). The potential role of ferroptosis in TAO pathogenesis is supported by the observation that ferroptosis-related pathways are activated in the disease. For example, the overexpression of SIRT6 in thyroid cancer has been shown to increase sensitivity to ferroptosis through nuclear receptor coactivator 4-dependent autophagic degradation of ferritin, suggesting a similar mechanism may be at play in TAO (104). Further supporting this hypothesis, differentially expressed ferroptosis-related lncRNAs, such as LINC01140 and ZFHX4-AS1, have been identified in TAO patients (45). These molecular insights highlight the potential of targeting ferroptosis pathways as a therapeutic strategy for TAO, aiming to mitigate oxidative stress and inflammation.

The application of ferroptosis-based therapies in treating TAO presents several safety concerns that must be addressed before clinical implementation. Ferroptosis, characterized by iron-dependent lipid peroxidation, can lead to unintended cytotoxicity in non-target tissues, potentially exacerbating oxidative stress and inflammation (110). The delicate balance between therapeutic efficacy and adverse effects necessitates rigorous preclinical and clinical evaluations. For instance, the use of ferroptosis inducers must be finely tuned to avoid excessive cell death in healthy ocular tissues, which could lead to complications such as vision impairment or loss (111). Additionally, the systemic effects of ferroptosis inducers, particularly their impact on iron metabolism and oxidative stress in other organs, must be carefully monitored to prevent off-target effects (112). The clinical implications of targeting ferroptosis in TAO are significant, given the current limitations of existing therapies. Traditional treatments for TAO, such as corticosteroids and immunosuppressants, often come with substantial side effects and variable efficacy. The introduction of ferroptosis inhibitors and modulators could offer a more targeted approach, potentially reducing the need for invasive procedures like orbital decompression surgery. Moreover, the development of biomarkers to monitor ferroptosis activity in patients with TAO could enhance the precision of treatment strategies, allowing for personalized therapeutic interventions (113). The financial implications associated with ferroptosis inhibitors, as emerging therapeutic modalities, necessitate substantial investment in research, development, and clinical trials. The elevated costs associated with novel pharmaceuticals may constrain their availability within clinical settings. Consequently, exploring the repurposing of existing drugs and the utilization of natural plant extracts could potentially mitigate treatment expenses. Furthermore, the extent of insurance coverage may influence patient acceptance and accessibility to these therapies. Patient acceptance of novel treatments, such as ferroptosis inhibitors, can be challenging due to their recent introduction and the limited knowledge patients may have regarding their efficacy and safety. Consequently, it is essential to enhance patient awareness and comprehension of this innovative therapy. Achieving this may necessitate comprehensive explanations and educational efforts by healthcare providers.

The design of clinical trials for ferroptosis modulators in TAO treatment presents several challenges. One critical aspect is the selection of appropriate biomarkers to monitor ferroptosis activity and therapeutic response. Biomarkers such as lipid peroxidation products and iron levels in ocular tissues could provide insights into the efficacy and safety of ferroptosis-based therapies (114). Furthermore, patient stratification based on genetic and molecular profiles may enhance the precision of these therapies, ensuring that only those likely to benefit are included in the trials (115). Another challenge is the potential variability in ferroptosis sensitivity among patients, which could affect treatment outcomes. Therefore, adaptive trial designs that allow for modifications based on interim results may be necessary to optimize dosing regimens and improve therapeutic efficacy (116).

The long-term efficacy of ferroptosis-based treatments for TAO remains an area of active investigation. While preliminary studies have shown promise, the durability of therapeutic effects and the potential for recurrence of TAO symptoms must be evaluated through extended follow-up periods (117). Continuous monitoring for signs of relapse and late-onset adverse effects is crucial to ensure sustained benefits and safety. Additionally, understanding the mechanisms underlying potential resistance to ferroptosis in TAO could inform combination therapies designed enhance and prolong treatment efficacy (107). For instance, combining ferroptosis inducers with immunomodulators or antioxidants may provide synergistic effects, reducing the likelihood of resistance (118).

In conclusion, ferroptosis represents a novel and promising therapeutic target in TAO. However, to successfully integrate this approach into clinical practice, it is essential to address the associated challenges, including safety, trial design, and long-term efficacy. Future research should focus on refining ferroptosis-based strategies to optimize therapeutic benefits while mitigating risks, ultimately improving outcomes for TAO patients.